COVID-19 Vaccine Manufacturers Are Not Enthusiastic About Using Defense Production Act
Executive Summary
Pfizer and Moderna execs note they have sufficient resources with their partners to meet their vaccine production commitments. J&J, which has a manufacturing arrangement with Sanofi, is ready to ship four million doses of its vaccine upon receiving authorization from FDA.
You may also be interested in...
Of Patents And Production: Industry-White House Row Over Vaccine Exports Highlights Policy Divide
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.
US Is Holding On To Its Supply Of AstraZeneca COVID-19 Vaccine
US is keeping a ‘small inventory’ of AstraZeneca’s vaccine so people in the US can receive it immediately following authorization, White House official says. President Biden seeks to boost vaccine manufacturing in India in parntership with India, Japan, and Australia.
Turning COVID-19 Vaccine EUA Into A BLA Will Require Six Months Of Additional Data
US FDA’s Peter Marks notes timeframe for sponsors to seek licensure at press call announcing emergency use authorization of J&J’s vaccine; Acting Commissioner Woodcock says effectiveness comparisons cannot be made between the three authorized vaccines since they have not been tested head-to-head.